NASDAQ:IPSC Century Therapeutics Q2 2025 Earnings Results & Report $1.47 +0.01 (+0.68%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.40 -0.07 (-4.76%) As of 10/9/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Century Therapeutics met analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.38 versus the -$0.38 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 14, 2025TimeBefore Market OpensConference Call4:00 PM ET Century Therapeutics EPS ResultsActual EPS-$0.38Consensus EPS -$0.38Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersCentury Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.03 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCentury Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Century Therapeutics Q2 2025 Earnings FAQ Did Century Therapeutics beat earnings estimates for Q2 2025? Century Therapeutics (NASDAQ:IPSC) reported earnings of -$0.38 per share for Q2 2025, matching the consensus estimate of -$0.38. The report was announced on Thursday, August 14, 2025. When is Century Therapeutics' next earnings date? Century Therapeutics' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Century Therapeutics on the company's earnings history page. Century Therapeutics Earnings HeadlinesCentury Therapeutics CNTY-813 Demonstrates Continued Advancement toward the Clinic Via Nonclinical Data Presented at EASD 2026October 5, 2026 | marketscreener.comMBurning Rock Biotech (NASDAQ:BNR) versus Century Therapeutics (NASDAQ:IPSC) Head-To-Head ContrastOctober 5, 2026 | americanbankingnews.comElon just declared war on your phoneSpaceX reportedly agreed to pay 8 billion dollars for a major slice of U.S. wireless spectrum, and shares of AT&T, Verizon, and T-Mobile dropped within hours of the news. Elon Musk called the deal the last critical piece for complete phone coverage in America, fueling speculation about a future device that could challenge the iPhone.October 10 at 1:00 AM | Stansberry Research (Ad)Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 BatchesOctober 5, 2026 | americanbankingnews.comBioStem Technologies (OTCMKTS:BSEM) vs. Century Therapeutics (NASDAQ:IPSC) Critical ComparisonOctober 4, 2026 | americanbankingnews.comCentury Therapeutics, Inc. Presents Nonclinical Data For CNTY-813 At EASDOctober 3, 2026 | marketscreener.comMSee More Century Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email. Email Address About Century TherapeuticsCentury Therapeutics (NASDAQ:IPSC) (NASDAQ:IPSC) is a biotechnology company developing allogeneic cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create potentially scalable immune-cell products designed to treat patients without relying on cells collected from each individual patient. Century’s research focuses primarily on iPSC-derived natural killer (NK) cells and T cells that are genetically engineered to recognize and attack cancer cells. Its pipeline has included investigational chimeric antigen receptor (CAR) cell therapies targeting blood cancers, including B-cell malignancies, with the goal of providing readily available, “off-the-shelf” treatments. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics conducts research and development activities in the United States. Its therapies remain investigational and are subject to clinical testing and regulatory review before they can be broadly marketed.View Century Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part Begins Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
